Simultaneous Integrated Boost by Volumetric Modulated Arc Therapy (VMAT) with Concurrent Mitomycin and Capecitabine in Anal Canal Carcinoma
Journal Title: Middle East Journal of Cancer - Year 2019, Vol 10, Issue 3
Abstract
Background: Combined treatment with radiotherapy and chemotherapy is the standard approach in non-metastatic anal carcinoma. Intensity-modulated radiotherapy and volumetric modulated arc therapy are currently the most accepted radiation techniques. We intend to report the clinical outcomes of patients that have been treated with volumetric modulated arc therapy concomitant with mitomycin C and capecitabine. Methods: This was a retrospective analysis of 11 patients diagnosed with anal carcinoma who received volumetric modulated arc therapy and a simultaneous integrated boost with concurrent chemotherapy. The chemotherapy protocol consisted of intravenous infusions of mitomycin C (12 mg/m2) on days 1 and 29, and oral capecitabine (825 mg/m2) twice daily with radiotherapy treatment. Results: Most patients had stage IIIB (45.4%) disease. The majority of patients (63.7%) received a dose of 59.4Gy per 33 fractions to the primary tumor and enlarged lymph nodes (median dose: 59.4 Gy; range: 54 Gy-61 Gy). The overall treatment period ranged between 34-56 days. All patients received the planned chemotherapy protocol of two cycles with the exception of one patient who received one cycle due hematologic toxicity and intolerance. Grade 3 skin toxicity occurred in three (27.3%) patients followed by grade 3 gastrointestinal toxicities in 18.2% of patients. Grade 2 anemia (18.2%), neutropenia (27.3%), and thrombocytopenia (27.3%) were observed in eight patients. Complete response was achieved in 90.9% of patients. Patients had an overall one-year survival of 89% and overall 3-year survival of 71% (95% CI: 20.75%- 38.49%). After the median follow up period of 12 months, patients had a progression-free survival of 75% (95% CI: 21.29%-38.6%) and 2-year colostomy free survival of 68% (95% CI: 17.2%-32.1%). Conclusion: Volumetric modulated arc therapy is a safe and effective modality of intensity modulated radiotherapy when combined with chemotherapy (mitomycin C and capecitabine) in anal cancer patients.
Authors and Affiliations
Engy M. Aboelnaga, Salwa Fathy, Mohamed A. Daoud
Keywords
Related Articles
- EP ID EP638899
- DOI 10.30476/mejc.2019.78573.
- Views 59
- Downloads 0
Non-Hodgkin’s Lymphoma Mimicking a Locally Advanced Renal Mass: A Case Report
Renal masses can be categorized as benign and malignant lesions. Among the renal malignancies, renal cell carcinoma is the most common malignancy. However, other rare malignant lesions should be considered in differentia...
The Effect of Placenta Growth Factor Knockdown on hsa-miR-22-3p, hsa-let-7b-3p, hsa-miR-451b, and hsa-mir-4290 Expressions in MKN-45- derived Gastric Cancer Stem-like Cells
Background: Placental growth factor is involved in human gastric cancer initiation and progression through stimulating the proliferation, angiogenesis, invasion and metastasis of cancerous cells. Previous studies indicat...
Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
Background: Metastatic prostate cancer is one of the most important cancers among men worldwide. Androgen ablation therapy can be used in treatment of these patients; however, most will progress to metastatic hormone-ref...
Priorities in Supportive Care Needs for Non-metastatic Cancer Patients Undergoing Chemotherapy in Iran: The Oncologists’ Perceptions
Background: Cancer patients undergoing chemotherapy have unmet needs. Oncologists play a central role in their supportive treatment. This study aims to describe Iranian oncologists' perceptions in terms of priorities in...
The Role of miR-143, miR-145, and miR-590 in Expression Levels of CD44 and Vascular Endothelial Cadherin in Oral Squamous Cell Carcinoma
Background: Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer with a continuing rise of incidence in developing countries. Despite the improvement in the clinical outcome of OSCC, the overall 5-...